Neuronetics and Greenbrook TMS Announce Definitive Agreement to Merge
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St rebounds with broad gains as oil slides sharply
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Neuronetics (STIM) PT Lowered to $3 at Canaccord Genuity
August 13, 2024 6:23 AM EDTCanaccord Genuity analyst William Plovanic lowered the price target on Neuronetics (NASDAQ: STIM) to $3.00 (from $6.00) while maintaining a Buy rating.
The analyst comments "Bottom line: STIMs Q2/24 missed estimates with $16.5M of revenue, driven by low treatment session revenue as customers delayed refilling inventory due to continued prior authorization and reimbursement headwinds from Change Healthcares cybersecurity breach impacting STIMs customer base. That said, STIM reiterated its FY24 revenue guidance of $78M-$80M, displaying confidence in the... More
